Compound 2 (KU-32) is a first-generation novologue (a novobiocin-based, C-terminal, heat shock protein 90 (Hsp90) inhibitor), that decreases glucose-induced death of primary sensory neurons and reverses numerous clinical indices of diabetic peripheral neuropathy in mice. The current study sought to exploit the C-terminal binding site of Hsp90 to determine whether the optimization of hydrogen bonding and hydrophobic interactions of second generation novologues could enhance neuroprotective activity. Using a series of substituted phenylboronic acids to replace the coumarin lactone of 2, we identified electronegative atoms placed at the meta-position of the B-ring exhibit improved cytoprotective activity, which is believed to result from favorable interactions with Lys539 in the Hsp90 C-terminal binding pocket. Consistent with these results, a meta-3-fluorophenyl substituted novologue (13b) exhibited a 14-fold lower ED 50 compared to 2 for protection against glucose-induced toxicity of primary sensory neurons.
Introduction
Approximately 26 million Americans are afflicted with either Type 1 or Type 2 diabetes. Despite the use of insulin and oral anti-diabetic medications to help maintain euglycemia, about 60-70% of these individuals develop diabetic peripheral neuropathy (DPN). 1 To date, approaches toward the treatment of DPN have centered on pathways/targets directly limited to hyperglycemia (i.e., polyol & hexosamine pathways, advanced glycation end products (AGEs), enhanced oxidative stress, PKC activation) 2 . Unfortunately, the contribution of these targets/pathways to the progression of DPN differs between individuals and does not concur with biochemical uniformity, and consequently, these approaches have resulted in little success for the management of DPN. As an alternative approach, we have explored the pharmacologic modulation of molecular chaperones to promote a broad cytoprotective response that may enhance a patient's ability to tolerate hyperglycemic insults and improve the symptoms of DPN.
Molecular chaperones, such as heat shock proteins 90 and 70 (Hsp90, Hsp70), are essential for folding nascent polypeptides into their biologically active structures and for the refolding of aggregated and denatured proteins that occur upon cellular stress. 3, 4 Numerous conditions that cause cell stress can also induce the "heat shock response" (HSR); the transcriptional upregulation of antioxidant genes and chaperones such as Hsp70. Importantly, small molecule inhibition of Hsp90 is sufficient to induce the HSR. Compound 2 (KU-32) 5, 6 is a small molecule Hsp90 C-terminal inhibitor that is based on novobiocin 1, a naturally occurring antimicrobial agent that inhibits DNA gyrase (Figure1) . Although the etiology of DPN is unrelated to the accumulation of one specific mis-folded or aggregated protein, hyperglycemia can increase oxidative stress and the oxidative modification of amino acids 7 that impair protein folding, 8 decrease mitochondrial protein import 9 and promote mitochondrial dysfunction. 2, 7a Even in the absence of a single, disease-specific protein aggregate, we have shown that pharmacologic induction of cytoprotective molecular chaperones can improve myelinated and unmyelinated fiber function in cellular models of glucotoxic stress and animal models of DPN. 10 Mechanistically, compound 2 was ineffective at preventing neuregulin-induced demyelination of myelinated cultures of sensory neurons prepared from Hsp70.1 and 70.3 double knockout mice, indicating that Hsp70 is necessary for the neuroprotective activity manifested by compound 2. Similarly, weekly treatment with 2 restored normal sensory and motor nerve function in diabetic wild type mice, but was unable to reverse multiple clinical indices of DPN in the diabetic Hsp70 knockout mice. 10 Collectively, these studies provide the biological and clinical rationale to support the modulation of molecular chaperones as a viable approach toward the treatment of DPN.
An enviable aspect of 2 is that it induces Hsp70 at concentrations well below those needed to inhibit Hsp90's protein folding ability, thus, it possesses a rather broad therapeutic window that dissociates cytoprotective properties from potentially cytotoxic effects resulting from the degradation of Hsp90-dependent client proteins. 4 We have previously shown that molecules containing a benzamide, as found in novobiocin, exhibit anti-proliferative activities, whereas molecules such as 2 containing an acetamide manifest neuroprotective properties. However, these prior studies sought to evaluate structure-activity relationships for novobiocin analogues as anti-cancer agents, 11, 12 rather than exploring chemical attributes that enhance the neuroprotective properties of novobiocin-based analogs. Therefore, the goal of this work was to determine whether diversification of the scaffold of compound 2 could identify structure-activity relationships (SAR) for novobiocin analogues (novologues) that enhance the neuroprotective properties manifested by Hsp90 C-terminal inhibitors.
Recently, we used molecular modeling and azide-containing novobiocin derivatives as photoaffinity probes to elucidate, for the first time, the Hsp90 C-terminal binding site. 13 As shown in Figure 2 (A-C), compound 2 docks to this region and appears to exhibit binding interactions with both the protein backbone and the amino acid side chains similar to those manifested by novobiocin. Interestingly, the coumarin lactone of 2 appears too distant from Lys539 to provide complementary interactions with this residue. In addition, the 3-amido side chain appears to project into a large hydrophobic pocket that could accommodate more flexible linkers. As a consequence of these observations, the novologue scaffold ( Figure 2D ) was designed to project the B-ring into the pocket wherein Lys539 resides and to serve as a lead compound for further diversification. In addition, the flexible ethyl amide projecting from the A-ring could accommodate a number of orientations that could better occupy the large hydrophobic pocket that remains vacant in the presence of 2.
Based on the novologue design, we envisioned construction of a parallel library to validate this scaffold for use as a neuroprotective agent. The library was designed so that the 3'-carbamate on noviose was omitted; based upon prior studies that showed this group to be detrimental to Hsp90 inhibitory activity. 5 In contrast, additional hydrophobic and hydrogen bonding interactions could be provided by the incorporation of functionalities onto the 3-aryl substituent (B-ring), which was designed to provide complementary interactions with Lys539. The 4-ethyl acetamide was included to occupy the binding pocket about the coumarin ring system. Consistent with data obtained from prior studies, the 7-noviosyl linkage was maintained as well the requisite 2',3'-diol. In this article, we report the parallel synthesis of rationally designed novologues as Hsp90 C-terminal inhibitors and assessment of their neuroprotective activities.
Results and Discussion
Retrosynthetically, a library of novologues was envisioned for construction via four components (Scheme 1); a resorcinolic benzaldehyde (3), a variety of commercially available boronic acids (4a-p), noviose (5) , and the acetamide side chain (Scheme 1). Prior work from our laboratory demonstrated that the trichloroacetimidate of noviose carbonate undergoes rapid coupling with phenols to give the desired α-anomer in high yield.
The boronic acids chosen for this study contain both electronic and steric moieties that could aid in elucidation of structure-activity relationships and provide crucial interactions with Lys539 and the surrounding pocket. Towards this goal, phenylboronic acids ( Figure 3 ) containing electronegative atoms at the meta-and para-positions were explored. In addition, hydrogen bond acceptors were included at these locations to provide potential hydrogen bonding interactions with the protonated form of Lys539. To serve as controls, hydrophobic groups (4j, 4k) and a tertiary amine (4l) were included in this series.
The synthesis of ethyl acetamide side chain containing novologues 13a-p, began with commercially available 2,4-dihydroxybenzaldehyde, 3. The 4-phenol of resorcinolic benzaldehyde 3 was protected as the corresponding benzyl ether 6, 14 and the 2-phenol converted to triflate 7 using trifluoromethanesulfonic anhydride and triethylamine (Scheme 2). Compound 7 was subsequently coupled with commercially available aryl boronic acids (4a-p) under standard Suzuki conditions 15, 16 to give biaryl ring systems 8a-p in good yields. Benzaldehydes 8a-p were converted to the corresponding nitrostyrenes (9a-p), following a Henry reaction with nitromethane and ammonium acetate. 17, 18 Reduction of the nitro and olefin functionalities with lithium aluminum hydride was followed by acylation of the resulting amines to afford acetamides 10a-p in good yields. The benzyl ether of compounds 10a-p was cleaved under hydrogenolysis conditions to afford phenols 11a-p, which were coupled with the tricloroacetimidate of noviose carbonate 12 5, 19 in the presence of a catalytic amount of boron trifluoride etherate. The resulting noviosylated biaryl systems were exposed to methanolic ammonia to solvolyze the cyclic carbonate and give the desired novologues (13a-p) in good to moderate yields.
In addition, two cyclohexene analogues 22a-b were pursued to test our hypothesis regarding the region surrounding the flexible side chain (Scheme 3). Although these molecules contain the same linker length, these analogues contain a bulky cyclohexane tether between the biaryl ring system and the acetamide.
Synthesis of cyclohexene analogues 22a-b began with the previously described phenol 6, which was protected as the methoxymethyl (MOM) ether 14 20 before the aldehyde of which was converted to nitrostyrene 15 under Henry conditions. 16 The electron deficient nitrostyrene (15) was subjected to a Diels-Alder cycloaddition with excess butadiene to give an enantiomeric mixture of cyclohexene derivative 16 in excellent yield. 21 The nitro group of 16 was selectively reduced to the amine via zinc dust and acidic isopropanol, 22 followed by acetylation to afford acetamide 17 in 71% yield over two steps. In order to construct the biaryl ring system, the MOM-ether was cleaved to give the phenol, which was then converted to the corresponding triflate, 19. A Suzuki reaction between 19 and 3-are inconsistent with our hypothesis that accommodation of the hydrophobic pocket would improve efficacy, the cyclohexene ring may exceed the space allowed in this binding cleft.
The data in Table 1 clearly support that the majority of novologues synthesized decrease neuronal toxicity induced by hyperglycemic stress. Although some of these compounds appear more effective than KU-32 at 1 μM, the differences were relatively minor. Therefore, to further scrutinize their efficacy, compounds exhibiting high neuroprotective activity were further evaluated for determination of EC 50 values. Since the difference in efficacy for novologues with meta-F and meta-CF3 substitutions on 13b and 13f were not significantly different from 2 or each other at 1 μM, the EC 50 values for these compounds were determined alongside 13h, 13l, 13n, and 13o. As shown in Figures 4A and 4B , EC 50 values were significantly improved upon closer inspection and clear distinctions were obtained. Novologue 13b yielded an EC 50 value (13.0 ± 3.6 nM) that was approximately 14-fold lower than compound 2 (240.2 ± 42.5 nM) or 13f (187.7 ± 43.5 nM). Similar results were also observed for novologue 13n, which exhibited an EC 50 value of 18.4 ± 3.2 nM. In contrast, novologue 13h which manifested similar efficacy to compound 2 at 1 μM, exhibited an EC 50 of 384 ± 108 nM, approximately 1.6-fold greater than 2.
The data in Figure 4 demonstrate that novologues 13b, 13i and 13n are more cytoprotective than the initial lead compound 2. Since we have previously shown that the cytoprotective activity manifested by compound 2 requires Hsp70, 10 we determined the ability of the novologues to induce Hsp70, relative to 2. To this end, a luciferase reporter assay was developed in which the expression of luciferase is driven by the human Hsp70 promoter containing two heat shock binding elements. 24 Since primary sensory neurons transfect poorly, an immortalized sensory neuron cell line (50B11 cells) was used for transfection. 25 Importantly, 50B11 cells have a very low basal level of Hsp70 expression, similar to primary sensory neurons. 26 Twenty-four hours after transfection with the reporter, cells were re-seeded into 12 well plates and incubated for an additional 24 h. The cells were then treated for 16 h with 10-1000 nM of the indicated novologues, cell lysates were prepared, luciferase activity assessed and luminescence normalized to total protein per well. Consistent with its increased efficacy in protecting against glucotoxicity, 13b was more effective than 2 at activation of the Hsp70 promoter ( Fig. 5A ) and also increased expression of Hsp70 protein at lower concentrations relative to KU-32 (Fig. 5B) . Although 13i had a similar EC 50 as 13b in preventing glucotoxicity, it only activated the Hsp70 promoter at 1 μM and the magnitude of this effect was no better than either 2 or 13b. However, it was surprising that despite the low EC 50 of 13n in protecting against glucotoxicity, 13n did not increase luciferase activity at any concentration tested nor did it increase Hsp70 protein expression as effectively as 2 or 13b. These results suggest that 13n likely affects Hsp70 levels indirectly and that the mechanism for neuroprotection may be distinct from that of related novologues.
Lastly, we mentioned that an attractive property of the modified novobiocin scaffold of 2 is that it induces Hsp70 at concentrations well below those needed to inhibit Hsp90's protein folding ability 10 . Therefore, to confirm that this new scaffold manifests similar activity, 13b was evaluated against MCF-7 breast cancer cells that are highly reliant upon the Hsp90 protein folding machinery. As can be observed, no client protein degradation occurred at concentrations up to 5 μM, indicating the potential for a large therapeutic window for this scaffold as well.
Conclusion
Using the recently reported model for the Hsp90 C-terminal binding site, a novologue scaffold was designed to afford putative interactions with previously unoccupied regions of the binding pocket, including Lys539. Through systematic replacement of substituents on the novologue B-ring (see Table 2 ), compound 13b was identified as a neuroprotective agent that exhibited ~14-fold greater efficacy against glucose-induced toxicity than the lead compound 2. The concentration of 13b needed to manifest neuroprotective activity correlated well with its ability to induce Hsp70 levels, and therefore linking cytoprotection to Hsp70 induction. When combined, these data demonstrate the rationally-designed novologue scaffold provides a promising platform on which diversification of the B-ring can lead to compounds that exhibit better neuroprotective activities.
General Experimental Methods

Preparation of Embryonic Dorsal Root Ganglion (DRG) Neuron Cultures
DRG from embryonic day 15--18 Sprague Dawley rat pups were harvested into Leibovitz's L15 medium (L15) and dissociated with 0.25% trypsin for 30 min at 37°C. The ganglia were sedimented at 1,000 × g for 5 min, resuspended in growth media [phenol red free Neurobasal medium (Gibco, Grand Island, NY) containing 25 mM glucose, 1X B-27 additive, 50 ng/ml nerve growth factor (NGF) (Harlan Bioscience, Indianapolis, IN), 4 mM glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin] and triturated with a firepolished glass pipette. The cells were cultured on collagen-coated (0.1 mg/mL collagen followed by overnight air drying in a laminar flow hood) black-walled 96-well plates (Corning Incorporated Corning, NY) at a seeding density of 2-3 × 10 4 cells per well. DRG neurons were re-fed the next day with fresh growth media containing 40 μM fluorodeoxyuridine and 10 μM cytosine β-D-arabinoside (both from Sigma Aldrich, St. Louis, MO) for 2 days to remove proliferating cells. Experiments were performed on DRG neurons on the third day in culture after placing the cells in fresh growth medium.
Glucotoxicity Assay
As immature DRG are susceptible to hyperglycemia-induced death 27 , an additional 20 mM glucose was added to the growth medium (yielding a total of 45mM glucose) for 4 hours. Preliminary experiments found that 20 mM excess glucose for 4 h was sufficient to induce a reproducible 40-50% loss in neuronal viability. As a result, the toxicity induced by the acute change in glucose concentration makes it a useful model for drug screening. 10, 28 Given the short time frame that the neurons are grown in vitro, they are not pure neuronal cultures but instead, highly enriched. Importantly, the contaminating SCs that remain in the culture are resistant to glucose-induced death as we and others have reported previously. 6 Unfortunately, the use of highly purified cultures is problematic since the cells extend neurites and establish connections with each other, thus becoming resistant to hyperglycemia-induced death. 6a DRG neurons were incubated overnight with the novologues in the presence of Neurobasal medium, 50 ng/ml NGF and antibiotics only. In order to monitor the efficiency of our the novologues in protecting DRG neurons against glucotoxicity, we made use of Calcein AM (Invitrogen, Carlsbad, CA) to measure cell viability. Hydrolysis of calcein AM to a fluorescent product can only occur in live cells. Excess glucose was added to the cultures for 4 h and cell viability was measured by incubating the cells with 2 μM calcein AM for 30 min in the dark at 37°C. Fluorescence was then measured using a plate reader with excitation and emission wavelengths set to 485nm and 520nm, respectively. The arbitrary fluorescence readings were normalized to the total amount of protein from each respective well of the neuronal cultures. The protein concentrations in each well were determined using the DC protein assay (Bio-Rad). Significant differences in the efficacy of the novologues for increasing cell viability were determined using a Kruskal-Wallis non-parametric ANOVA and Dunn's post-test.
Luciferase Reporter Assay and Client Protein Degradation
A 1.5 kb region upstream of the start codon of the human HSPA1A gene was synthesized by GeneArt (Life Technologies, Grand Island, NY) and a 5' Kpn I and 3' Sac I sites added to direct cloning into the pGL3 basic luciferase reporter plasmid. DNA sequencing verified the integrity of the promoter sequence and the presence of two heat shock elements. 50B11 cells 25 were grown in 10 cm dishes in DMEM containing 25 mM glucose, 10% FCS and 5 μg/ml blasticidin. The cells were transfected using lipofectamine and after 24 h, were reseeded into 24 well plates at a density of 2 × 10 5 cells per well. The cells were permitted to attach to the plate for 6 h in growth medium and treated with the indicated concentrations of the various novologues for 16 h. Luciferase activity was assessed and normalized to the total protein concentration of each well. Results shown are from triplicate wells obtained in at least three separate experiments. Preliminary experiments validated that the reporter was strongly activated as expected by either heat shock (~ 10 fold) or 250 nM geldanamycin (~4-5 fold). Client protein degradation in MCF7 cells was performed as we have previously described.
Molecular Modeling-Surflex-Dock in Sybyl v8.0 was used for molecular modeling and docking studies. A homology model of Hsp90α based on the open HtpG SAXS structure was used as the receptor, while the protomol was generated using docked Novobiocin as described in reference. 13 The energy minimized molecules were then docked with 10 different starting conformations while rotation of rotatable bonds was unrestricted. Visual interpretation and figure preparation were then carried out in Pymol.
Chemistry General-1 H NMR were recorded at 400 or 500 MHz (Bruker DRX-400 Bruker with a H/C/P/F QNP gradient probe) spectrometer and 13 C NMR spectra were recorded at 125 MHz (Bruker DRX 500 with broadband, inverse triple resonance, and high resolution magic angle spinning HR-MA probe spectrometer); chemical shifts are reported in δ (ppm) relative to the internal reference chloroform-d (CDCl 3 , 7.27 ppm). FAB (HRMS) spectra were recorded with a LCT Premier (Waters Corp., Milford, MA). The purity of all compounds was determined to be >95%as determined by 1 H NMR and 13 C NMR spectra, unless otherwise noted. The most active 5 compounds were verified for >95% purity by HPLC analyses. TLC was performed on glass backed silica gel plates (Uniplate) with spots visualized by UV light. All solvents were reagent grade and, when necessary, were purified and dried by standard methods. Concentration of solutions after reactions and extractions involved the use of a rotary evaporator operating at reduced pressure.
5-(Benzyloxy)-2-formylphenyl trifluoromethanesulfonate (7):
Triethylamine (1.02 mL, 7.35 mmol) followed by triflic anhydride (1.38 mL, 6.35 mmol) were added simultaneously to a phenol 6 (1.12 g, 4.91 mmol) in anhydrous CH 2 Cl 2 (10 mL) at 0 °C. Upon completion of the reaction, quenched by the addition of water (50 mL), extracted with CH 2 Cl 2 (3 × 15 mL), washed with saturated aqueous sodium chloride solution, dried over anhydrous Na 2 SO 4 , filtered and concentrated. The residue was purified by column chromatography (SiO 2 , 4:1, Hex:EtOAc) to afford triflate 7 as a yellow oil (1.06 g, 60%).
General procedure for Suzuki coupling reaction of triflate 3 and boronic acids 4a-p:
5-(Benzyloxy)-[1,1'-biphenyl]-2-carbaldehyde (8a):
Tetrakis(triphenylphosphine)palladium(0) (70.4 mg, 0.068 mmol) was added to a mixture of triflate 7 (0.246 g, 0.68 mmol), phenylboronic acid 4a (92 mg, 0.75 mmol), and K 2 CO 3 (0.169 g, 1.2 mmol) in DMF (6.8 mL) under argon atmosphere in a sealed tube. The resulting reaction mixture was sealed and heated to reflux for 16 h. The reaction was cooled to room temperature, quenched with saturated sodium bicarbonate, extracted with EtOAc (3 × 5 mL), washed with saturated aqueous sodium chloride, dried over anhydrous Na 2 8, 148.6, 137.8, 136.0, 130.0, 128.8, 128.4, 127.6, 116.3, 114.7, 70.4; HRMS (FAB) 190.7, 162.9, 161.7, 147.2, 140.1, 136.0, 130.5, 129.0, 128.6, 127.8, 126.0, 117.1, 116.9, 116.4, 115.5, 115.1, 70.6 9, 162.8, 147.4, 136.0, 131.7, 131.6, 130.5, 128.8, 128.5, 127.7, 127.6, 116.5, 115.6, 115.4, 114.7, 70.4 3, 162.9, 145.1, 136.8, 135.9, 133.5, 131.6, 130.0, 129.8, 129.6, 128.8, 128.4, 127.6, 127.6, 126.9, 116.7, 115 4, 162.8, 146.8, 139.7, 135.9, 134.5, 130.5, 129.8, 129.7, 128.8, 128.5, 128.4, 128.3, 127.6, 127.5, 116.3, 115.0, 70.4 4, 163.0, 146.8, 138.8, 135.9, 133.4, 131.0, 130.9, 129.0, 129.0, 128.6, 127.8, 127.6, 126.6, 126.5, 125.2, 116.7, 115.2, 70.6 2, 162.9, 146.7, 141.7, 135.9, 130.8, 130.3, 128.9, 128.6, 127.7, 127.5, 125.5, 125.4, 122.8, 116.6, 115.1, 70.5 2'-(methylthio)-[1,1'- 8, 163., 146.3, 138.4, 136.2, 136.1, 130.4, 129.5, 129.1, 128.8, 128.4, 127.8, 127.7, 124.7, 124.6, 116.4, 115.3, 70.4, 15.6 5, 163.1, 156.6, 144.5, 136.2, 131.4, 130.1, 129.2, 128.8, 128.4, 127.9, 127.7, 126.8, 121.0, 116.9, 114.5, 110.8, 70.3, 55.5 4, 162.8, 148.9, 138.3, 137.9, 136.2, 130.9, 130.1, 129.2, 128.9, 128.5, 128.5, 127.8, 127.3, 116.3, 114.8, 70.5, 21.7 162.7, 148.5, 138.3, 137.8, 136.0, 130.7, 130.2, 129.1, 128.8, 128.4, 127.6, 127.6, 116.4, 114.5, 70.4, 67.1, 63.2, 53.7 2, 162.7, 156.0, 148.4, 136.1, 131.2, 130.6, 130.0, 128.7, 128.3, 127.6, 127.5, 120.0, 116.1, 114.3, 70.3, 25.7, 18.3, 4.3 2, 162.8, 148.2, 147.9, 147.9, 136.1, 131.6, 130.2, 128.8, 128.4, 127.7, 127.6, 124.0, 116.2, 114.5, 110.3, 108.3, 101.5, 70.4; HRMS (FAB) 8, 165.3, 160.5, 135.8, 131.2, 129.0, 128.7, 127.8, 120.0, 109.5, 102.1, 91.0, 70.8; HRMS (FAB) .7, 162.9, 149.8, 145.8, 145.2, 135.7, 131.0, 128.8, 128.5, 127.6, 127.1, 124.6, 116.3, 115.4, 70.5; HRMS (FAB) 138.1, 136.4, 136.3, 135.5, 131.8 131.7, 129.9, 129.2, 128.8, 128.0, 121.3, 117.3, 116.3, 116.0, 115.6, 70.7 5, 145.4, 141.4, 137.6, 136.1, 136.0, 130.5, 130.4, 129.6, 128.6, 127.7, 125.7, 121.0, 116.9, 116.6, 115.6, 115.4, 70.5 5, 145.7, 137.8, 136.1, 136.0, 131.5, 131.4, 129.6, 128.9, 128.5, 127.7, 121.0, 117.0, 115.9, 115.7, 115.3, 70.4 4, 143.8, 137.7, 137.0, 135.9, 133.2, 131.4, 130.0, 130.0, 129.3, 128.7, 128.3, 127.6, 127.1, 123.4, 121.5, 117.1, 115.6, 70.3 )-3'-chloro-2-(2-nitrovinyl)-1,1'-biphenyl (9e 4, 136.1, 134.7, 129.9, 129.6, 129.6, 129.5, 129.0, 128.8, 128.5, 128.4, 128,0, 127.6, 120.9, 116.9, 115.5, 109.9, 70.4 2-(2-nitrovinyl)-3'-(trifluoromethyl)-1,1'- 4, 147.8, 144.9, 144.3, 139.8, 138.6, 137.1, 136.4, 135.8, 133.5, 131.2, 129.5, 129.1, 128.8, 128.5, 127.6, 124.2, 120.8, 120.4, 117.0, 115.6, 70.4 4, 143.7, 138.8, 136.3, 135.3, 131.4, 130.4, 128.9, 128.4, 127.7, 122.0, 121.1, 117.5, 115.1, 111.4, 70.4, 55.6 
5-(Benzyloxy)-
2.5 Hz, 1H), 6.91 -6.86 (m, 2H), 6.83 -6.79 (m, 1H), 6.03 (s, 2H), 5.15 (s, 2H); 13 C NMR (125 MHz, CDCl 3 ) δ 191.
5-(Benzyloxy
(E)-5-(Benzyloxy)-
(E)-5-(Benzyloxy)-3'-methoxy-2-(2-nitrovinyl)-1,1'-biphenyl (9j):
1 H NMR (500 MHz, CDCl 3 ) δ 8.04 (d, J = 13.6 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H), 7.46 -7.37 (m, 6H), 7.07 -7.02 (m, 3H), 7.02 -6.97 (ddd, J = 8.2, 2.6, 0.9 Hz, 1H), 6.88 -6.84 (m, 1H), 6.84 -6.80 (dd, J = 2.6, 1.6 Hz, 1H), 5.15 (s, 2H), 3.85 (s, 3H); 13 C NMR (125 MHz, CDCl 3 ) δ 161. 5, 159.8, 146.8, 140.6, 138.2, 136.2, 135.9, 129.9, 129.5, 129.0, 128.6, 127.7, 122.3, 121.1, 116.8, 115.4, 115.4, 114.1, 70.5, 55.6 4, 135.8, 130.4, 129.5, 129.3, 128.9, 128.7, 128.5, 127.8, 127.8, 126.9, 121.1, 116.8, 115.3, 77.5, 77.4, 77.2, 77.0, 70.5 21.7 5'-(Benzyloxy)-2'-(2-nitrovinyl)-[1,1'-biphenyl]-3-yl) 8, 130.6, 129.5, 129.3, 128.9, 128.8, 128.5, 128.4, 127.7, 121.0, 116.9, 115.1, 70.4, 67.1, 63.3, 53.8 5'-(Benzyloxy)-2'-(2-nitrovinyl)-[1,1'-biphenyl]-4-yl) 4, 148.0, 147.9, 146.5, 138.1, 136.1, 135.7, 132.9, 129.5, 128.8, 128.4, 127.6, 123.6, 121.0, 116.7, 115.0, 109.9, 108.5, 101.5, 70.3; HRMS (FAB) 5, 149.9, 149.6, 142.8, 136.9, 136.8, 136.3, 135.8, 134.8, 129.7, 128.8, 128.5, 127.6, 123.4, 121.1, 117.1, 115.8, 70.4 2, 150.2, 147.0, 143.7, 136.7, 136.6, 135.8, 128.9, 127.6, 124.5, 120.7, 116.8, 116.1, 70.6 
(E)-4-((
(E)-((
General procedure for preparation of 10a-p from 9a-p
N-(2-(5-(Benzyloxy)-[1,1'-biphenyl]-2-yl)ethyl)acetamide (10a):
Nitrostyrene 9a (182 mg, 0.55 mmol) in THF (0.7 mL) was added dropwise to a solution of Lithiumaluminium hydride (42 mg, 1.12 mmol) in THF (2 mL) under organ atmosphere at RT. Upon completion (nearly immediately) the reaction was quenched by the addition of water (42 μL), 3M NaOH (42 μL), and water (84 μL). The resulted mixture was filtered through a plug of celite, washed with CH 2 Cl 2 , and dried over K 2 CO 3 . Upon filtration the mixture was concentrated to oil and used without further purification. Acetic anhydride (58 μL, 0.62 mmol) and triethylamine (93 μL, 0.67 mmol) were added to a solution of the crude amine in CH 2 Cl 2 (5.6 mL) under an organ atmosphere at RT. After 3 h the reaction was quenched with saturated aqueous ammonium chloride and extracted with CH 2 Cl 2 (3 × 10 mL); combined organic fractions were washed with saturated aqueous sodiumchloride, dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by column chromatography (SiO 2 ; 3:1, Hex:EtOAc) to afford acetamide 10a (0.12 g, 0.35 mmol, 64%). 1 H NMR (400 MHz, CDCl 3 ) δ 7. 8H), 2H), 7.23 (d, J = 8.4 Hz, 1H), J = 8.4, 2.7 Hz, 1H), 6.93 (d, J = 2.7 Hz, 1H), 5.71 (br s, NH), 5.08 (s, 2H), (q, J = 7.0 Hz, 2H), 2.89 -2.64 (t, J = 7.2 Hz, 2H), 1.85 (s, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 170. 2, 157.2, 143.4, 141.4, 137.0, 130.8, 129.1, 128.7, 128.6, 128.4, 128.0, 127.6, 127.2, 116.6, 114.2, 70.1, 40.7, 31.9, 23.2 N-(2-(5-(Benzyloxy)-3'-fluoro-[1,1'-biphenyl]-2-yl) 3, 157.3, 143.7, 142.2, 136.9, 131.0, 130.1, 123.0, 128.8, 128.6, 128.2, 127.7, 125.0, 116.5, 116.4, 114.6, 114.4, 70.2, 40.8, 32.0, 23.3 5, 157.3, 142.4, 137.0, 130.9, 130.8, 130.7, 128.7, 128.7, 128.2, 127.7, 116.8, 115.5, 115.3, 114.3, 70.2, 40.8, 32.0, 23 Na, calcd, 386.1527; found, 386.1529 . 4, 139.8, 136.9, 133.1, 131.3, 130.4, 129.6, 129.0, 128.6, 128.0, 127.6, 126.8, 116.4, 114.9, 70.1, 40.3, 31.8, 22.9 6, 157.5, 143.2, 142.1, 136.9, 134.3, 131.1, 129.9 129.3, 128.8, 128.3, 127.7, 127.6, 127.5, 116.7, 114.8, 70.3, 46.1, 41.3, 31.7, 22.5, 8.8 7, 157.4, 142.2, 141.9, 136.9, 132.6, 131.1, 129.0, 128.8, 128.5, 128.2, 127.7, 124.2, 116.7, 114.8, 70.3, 40.8 31.9, 23. CDCl 3 ) δ 170.3, 157.1, 145.1, 141. 8, 136.8, 130.9, 129.5, 129.1, 128.6, 128.6, 127.5, 125.6, 125.2, 125.2, 122.9, 116.4, 114.6, 70.1, 40.6, 31.9 ; HRMS m/z: [M + Na + ] for C 24 H 22 F 3 NO 2 Na, calcd, 436.1495; found, 436.1489 . Benzyloxy)-2'-(methylthio)-[1,1' -biphenyl]-2-yl)ethyl)acetamide (10h): 1 H NMR (400 MHz, CDCl 3 ) δ 7.48 -7.30 (m, 7H), 7.28 -7.18 (m, 2H), 7.14 (s, 1H), 7.03 -6.98 (ddd, J = 8.5, 2.8, 1.0 Hz, 1H), 6.87 -6.83 (m, 1H), 5.63 (br s, NH), 5.05 (s, 2H), 3.43 -3.16 (ddt, J = 42.5, 13.3, 6 .6 Hz, 2H), 2.66 -2.52 (t, J = 6.7 Hz, 2H), 2.39 (d, J = 1.0 Hz, 3H), 1.84 (d, J = 1.0 Hz, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 170. 3, 157.3, 141.1, 139.1, 137.6, 137.0, 130.6, 129.8, 129.4, 128.7, 128.4, 128.1, 127.7, 124.5, 124.0, 116.5, 115.2, 70.2, 40.1, 31.7, 23.3, 15.2 2, 156.4, 139.9, 137.1, 131.2, 130.1, 129.2, 128.7, 128.1, 127.8, 120.9, 116.8, 114.4, 111.2, 70.1, 55.8, 40.4, 31.9, 23.5 ; HRMS m/z: [M + H + ] for C 24 H 26 NO 3 , calcd, 376.1913; found, 376.1902 . 5, 157.2, 143.3, 142.9, 137.0, 130.8, 129.5, 128.7, 128.1, 128.1, 127.7, 121.6, 116.5, 114.9, 114.3, 112.7, 70.17, 55.4, 40.8, 32.0, 23.3 2, 143.5, 141.4, 138.0, 137.0, 130.7, 129.9, 128.7, 128.7, 128.3, 128.1, 128.0, 127.6, 126.2, 116.5, 114.2, 70.1, 40.8, 31.9, 23.3, 21.6 ; ESI-HRMS m/z calculated for C 24 3, 143.4, 141.5, 138.0, 137.1, 130.9, 123.0, 128.7, 128.7, 128.4, 128.2, 128.2, 128.0, 127.7, 116.8, 114.1, 70.2, 67.1, 63.5, 53.8, 40.6, 32.1, 23.4 Hz, 3H), 7.36 -7.31 (m, 1H), 7.21 -7.14 (m, 3H), 6.94 -6.86 (m, 2H), 5.08 (s, 2H), 3.34 -3.23 (q, J = 6.7 Hz, 2H), 2.75 (t, J = 7.1 Hz, 2H), 1.74 (s, 3H), 1.97 (s, 9H), 0.25 (s, 6H); 13 C NMR (125 MHz, CDCl 3 ) δ 169. 9, 157.3, 155.0, 143.3, 137.2, 134.5, 130.8, 130.2, 128.7, 128.1, 127.7, 120.0, 116.8, 114.0, 70.2, 53.6, 40.7, 32.1, 25.8, 23.4, 18.4, HRMS (FAB) 1.87 (s, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 170. 4, 157.2, 147.5, 146.8, 143.0, 137.0, 135.2, 130.8, 129.3, 128.8, 128.1, 127.6, 123.2, 122.4, 116.7, 114.1, 109.7, 108.3, 101.2, 70.1, 40.7, 31.9, 23.2; HRMS (FAB) 8.52 (dd, J = 18.2, 4.0 Hz, 2H), J = 7.8, 2.0 Hz, 1H), 7H), J = 8.5, 2.8 Hz, 1H), 6.84 (d, J = 2.8 Hz, 1H), 5.06 (s, 2H), J = 6.5 Hz, 2H), J = 8.1, 6 .6 Hz, 2H), 1.90 (s, 3H); 13 C NMR (125 MHz, CDCl 3 ) δ 170. 1, 157.5, 149.6, 148.5, 139.5, 136.9, 131.2, 129.0, 128.8, 128.3, 127.7, 123.5, 116.9, 115.0, 70.3, 40.7, 32.2, 23.5; HRMS (FAB) 4, 158.1, 156.3, 137.2, 132.3, 132.2, 130.8, 128.7, 128.5, 129.7, 127.5, 117.9, 106.2, 103.0, 69.9, 41.1, 29.7, 29.6, 23.1; HRMS (FAB) (3.5 mL) and the solution was placed under an atmosphere of H 2 . After 12 h, the solution was diluted with CH 2 Cl 2 and filtered through Celite. The eluent was concentrated to afford a yellow solid, which was purified by column chromatography (SiO 2 , 100:5, CH 2 Cl 2 :MeOH) to afford phenol 11a (64 mg, 0.25mmol, 79%) as a pale yellow amorphous solid. 1 H NMR (400 MHz, CDCl 3 ) δ 7. 5H), 1H), 6.90 (d, J = 8.3 Hz, 1H), 6.64 (d, J = 8.3 Hz, 1H), 6.59 (d, J = 2.5 Hz, 1H), 5.61 (t, J = 5.5 Hz, 1H), 2H) , 2.55 (t, J = 7.1 Hz, 2H), 1.66 (s, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 171. 2, 155.2, 143.4, 141.6, 130.8, 129.1, 128.4, 127.2, 127.2, 117.4, 115.0, 41.1, 31.8, 23.2 Na, calcd, 278.1151; found, 278. (125 MHz, MeOD) δ 173.1, 164.8, 162.9, 156.7, 145.5, 143.3, 132.0, 131.0, 128.3, 126.1, 117.6, 115.9, 114.7, 41.8, 32.8, 22.5 Na, calcd, 296.1063; found, 296. 2H), 3H), 6.71 (dd, J = 8.3, 2.5 Hz, 1H), 6.56 (d, J = 2.5 Hz, 1H), 3.07 (t, J = 7.6 Hz, 2H) , 2.60 (t, J = 7.6 Hz, 2H), 1.78 (s, 3H); 13 C NMR (100 MHz, MeOD) δ 173.0, 156.7, 143.5, 139.2, 131.9, 131.9, 131.8, 128.5, 117.8, 130.9, 129.5, 127.3, 121.7, 117.2, 115.1, 115.0, 112.6, 55.4, 41.1, 31.8, 23.3; HRMS m/z: [M + H + ] for C 17 H 20 NO 3 , calcd, 286.1443; found, 286.1436 . Hydroxy-3'-methyl-[1,1' -biphenyl]-2-yl)ethyl)acetamide (11k): 1 H NMR (400 MHz, CDCl 3 ) δ 7. 50 (br s, OH), 1H), 7.15 (d, J = 7.6 Hz, 1H), 3H), 6.80 (d, J = 7.6 Hz, 1H), 6.73 (s, 1H), 5.53 (br s, NH), J = 6.7 Hz, 2H) , 2.71 (t, J = 7.0 Hz, 2H), 2.37 (s, 3H), 1.85 (s, 3H); 13 C NMR (1001 MHz, CDCl 3 ) δ 170. 9, 155.0, 143.6, 141.6, 138.1, 130.8, 1230.0, 128.3, 128.0, 127.4, 126.3, 117.4, 114.9, 41.1, 31.8, 23.3, 21.7 ; HRMS m/z: [M + Na + ] for C 17 H 19 NO 2 Na, calcd, 292.1308; found, 292.1314 . Hydroxy-3'-(morpholinomethyl)-[1,1'-biphenyl]-2-yl) 3.53 (s, 3H), J = 6.7 Hz, 2H) , 2.69 (t, J = 7.0 Hz, 2H), 2.49 (t, J = 4.8 Hz, 4H), 1.87 (s, 3H); 13 C NMR (125 MHz, CDCl 3 ) δ 170. 5, 155.0, 143.4, 141.7, 130.9, 130.2, 128.4, 128.2, 117.5, 115.0, 66.9, 63.4, 53.8, 40.8, 32.0, 23.4 J = 6.7 Hz, 2H), J = 8.2 Hz, 1H) , 7.00 (br s, OH), 6. J = 8.4 Hz, 2H), 2H), 5.38 (s, 1H), (q, J = 6.6 Hz, 2H), 2.78 -2.64 (t, J = 6.9 Hz, 2H), 1.93 -1.81 (s, 3H), 1.00 (s, 9H), 0.24 (s, 6H); 13 C NMR (125 MHz, CDCl 3 ) δ 170.7, 155.0, 154.9, 143.3, 134.6, 130.9, 130.3, 127.8, 120.0, 117.5, 114.7, 41.0, 32.0, 26.0, 23.4, 18.4, HRMS (FAB) SiNa, calcd, 408.1965; found, 408.1960 . 5, 146.8, 143.0, 135.4, 130.8, 127.4, 122.4, 117.5, 114.9, 109.8, 108.3, 101.2, 41.1, 31.9, 23.3; HRMS (FAB) 9 Hz, 1H), J = 8.0, 4.8 Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), J = 8.3, 2.7 Hz, 1H), 6.73 (d, J = 2.7 Hz, 1H), 5.82 (t, J = 5.9 Hz, 2H), (q, J = 6.8 Hz, 2H), 2.69 (t, J = 7.2 Hz, 2H), 1.85 (s, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 170. 7, 156.1, 149.1, 147.7, 138.8, 138.0, 131.4, 127.3, 123.7, 117.5, 116.4, 100.2, 40.9, 32.0, 23.4; HRMS (FAB) 157.1, 152.8, 149.7, 149.6, 141.3, 132.4, 128.0, 126.2, 117.2, 117.1, 116.9, 41.8, 32.8, 22.5; HRMS (FAB) General procedure for activated Noviose carbamate coupling and followed by methanolysis of compounds 11a-p: Borontrifluoride etherate (6.2 μL, 0.05 mmol) was added to 11a (0.25 mmol) and activated noviose (0.2 mmol) in 2.5 mL anhydrous CH 2 Cl 2 . After stirring at room temperature for 2 h, triethylamine (150 μL) was added and concentrated. The residue was partially purified via column chromatography (SiO 2 , 100:8 CH 2 Cl 2 :acetone) to give noviose coupled product as a colorless foam, which was used directly for next step. Triethylamine (0.22 mL, 10%) was added to the cyclic carbonate (100 mg, 0.22 mmol) in MeOH (2.2 mL). After 12 h, the solvent was concentrated and the residue was purified via column chromatography (SiO 2 , 10:1, CH 2 Cl 2 :Acetone) to afford inseparable diastereomers 13a (see following experimental section for diastereoselectivities) as a colorless amorphous solids. Compounds 13b-m were synthesized using this procedure. 5-(((3R,4S,5R) 3, 155.4, 143.5, 141.4, 130.8, 129.5, 129.2, 128.5, 127.4, 118.2, 115.2, 98.1, 84.5, 78.4, 71.5, 68.8, 62.0, 40.8, 32.1, 29.2, 23.4, 23 93.8, 84.2, 76.0, 71.3, 71.1, 62.0, 40.4, 32.0, 28.6, 23.3, 18.5 8, 130.8, 130.7, 129.5, 118.1, 115.4, 115.3, 115.3, 97.9, 84.4, 78.3, 71.4, 68.7, 62.0, 40.6, 32.1, 29.1, 23.4, 23.1 ; HRMS m/z: [M + Na + ] for C 24 H 30 FNO 6 , calcd, 470.1955; found, 470.1958 . 4, 143.4, 141.5, 137.8, 130.9, 130.1, 129.6, 128.5, 128.3, 128.2, 118.2, 115.3, 98.1, 84.6, 78.4, 71.5, 68.8, 67.1, 63.5, 62.0, 53.8, 40.7, 32.2, 29.2, 23.5, 23.2; HRMS (FAB) Na, calcd, 551.2728; found, 551.2734 . 5-(((3R,4S,5R )-3,4-Dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-4'-hydroxy-[1,1'-biphenyl]-2-yl)ethyl)acetamide (13m): After cyclic carbonate hydrolysis following the same procedure as compound 13a, the crude TBS protected compound was dissolved in THF (2 mL) and tertrabutylammonium fluoride (1.5 eq.) was added drop wise at 0 °C under argon atmosphere. After 1 h the reaction was quenched with Chemical structures of novobiocin 1 and 2 (KU-32). Boronic acids selected for incorporation into novologue X scaffold. A) DRG sensory neurons were incubated in the absence or presence of 0.1-1000 nM of the indicated novologue overnight and then subjected to 4 hrs of hyperglycemia. Cell viability was measured as described in Experimental Methods and the data expressed as percent of normoglycemic controls. Under hyperglycemic conditions and in the absence of any novologues, cell viability was 20% ± 7. B) The EC 50 was determined using the EC anything function of GraphPad Prism 5.0 and the mean ± SEM (n=3-8) is shown. #, p< 0.05 versus compound 2.
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Figure. 5. Induction of Hsp70 by select novologues in the absence of client protein degradation
A) 50B11 cells were transfected with a luciferase reporter whose expression was drive by the human Hsp70 promoter. The cells were treated with the indicated concentration of select novologues for 16 hr and luciferase activity assessed. **, p < 0.01 and ***, p < 0.001 versus control; ^, p < 0.05 and ^^^, p< 0.001 versus compound 2 at same concentration. B) DRG sensory neurons were incubated in the presence of DMSO (Cntrl) or 10-1000 nM of the indicated novologue overnight and then subjected to 4 hrs of hyperglycemia. The neurons were harvested and Hsp70 and β-actin levels were determined by immunoblot analysis. Band intensity was quantified using Image J, Hsp70 expression was normalized to the level of β-actin and expressed as a fold control. C) MCF7 cells were treated with the indicated concentrations of 13b for 24 hr, cell lysates were prepared and the levels of the Hsp90 client proteins, Her2, Raf, and Akt determined by immunoblot analysis. As a positive control, some cells were treated with 500 nM geldanamycin (GDA) to induce client protein degradation. The level of β-actin verified equivalent protein loading. Table 1 Cell viability data of ethyl acetamide side chain novologues. 
